Brief: Creative Medical Technology Holdings Engages Highly Respected International Cro For Phase 1 / 2 Clinical Trial To Treat Type 1 Diabetes Using Celz-201
07/03/2023 13:25
March 7 (Reuters) - Creative Medical Technology Holdings
Inc CELZ.O :
* CREATIVE MEDICAL TECHNOLOGY HOLDINGS ENGAGES HIGHLY
RESPECTED
INTERNATIONAL CRO FOR PHASE 1 / 2 CLINICAL TRIAL TO TREAT TYPE 1
DIABETES USING CELZ-201
Source text for Eikon: ID:nBwZQBhZa
Further company coverage: CELZ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Creative Medical Technology Holdings
See all newsBrief: Creative Medical Technology Buys 4 Million Biodefense Shares For $200,000 Cash And 1 Million Shares On Sept 24
Brief: Creative Medical Technology Holdings Successfully Completes Enrollment And Treatment Across Entire FDA-Cleared Adapt Trial, Including Opioid Cohort, Advancing Celz-201 / Olastrocel Toward Rmat Evaluation And Phase 3 Planning
Creative Medical Technology Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
NASDAQ RESUMED AT 11:07 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:02 AM